CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,425 enrolled
Drug / intervention
urapidildrug
Likely dose
urapidil 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03790800
NCT03790800Phase 3Completed
CompareCT.gov

Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

The George Institute for Global Health, China·interventional·Posted Jan 2, 2019·Updated Mar 26, 2025

In Brief

A Phase 3 clinical trial evaluating urapidil for Stroke, Acute and Cerebrovascular Disorders. Completed, enrolled 2,425 participants across 4 sites.

Detailed Summary

A multicentre, ambulance-delivered, prospective, randomized, open-label, blinded endpoint (PROBE) study to assess the effects of hyperacute intensive blood pressure (BP) lowering initiated in ambulance setting on (i) functional outcome in patients with acute stroke (ii) safety in patients with confirmed acute stroke and other conditions that were initially suspected as acute stroke (i.e. stroke mimic).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Acute, Cerebrovascular Disorders
CountriesChina
CollaboratorsShanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, Sichuan Academy of Medical Sciences

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 2, 2019
Enrollment StartMar 20, 2020
Primary CompletionNov 23, 2023
Study CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 7.5 years ago

Interventions

urapidildrug

A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists \>150 after 5 minutes.